Gennex Laboratories Ltd
Gennex Laboratories Ltd (GENNEX) last traded at ₹12.2, a market capitalisation of ₹296 crore, on a P/E of 15.8. Over the past 52 weeks the stock has ranged between ₹7.05 and ₹17.2. Gennex Laboratories Ltd last reported results for the quarter ended Jun 2026, with sales of ₹39.84 crore and net profit of ₹4.67 crore. Figures are as of 25 Aug 2026 and are not real time.
Gennex Laboratories Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Gennex Laboratories Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹39.84 cr, up 16.6% from ₹34.18 cr a year earlier. Net profit was ₹4.67 cr, down 6.8% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 33.38 | 40.01 | 40.33 | 34.18 | 39.3 | 42.96 | 60.96 | 39.84 |
| Expenses | 25.92 | 32.86 | 38.31 | 29.11 | 31.74 | 34.39 | 55.07 | 35.46 |
| Operating profit | 7.46 | 7.15 | 2.02 | 5.07 | 7.56 | 8.57 | 5.89 | 4.38 |
| OPM % | 22.35% | 17.87% | 5.01% | 14.83% | 19.24% | 19.95% | 9.66% | 10.99% |
| Other income | 0 | 0 | 3.68 | 2.28 | 0 | -0.3 | 1.02 | 2.01 |
| Interest | 0.22 | 0.84 | 1.2 | 0.98 | 1.03 | 1.11 | 1.08 | 0.57 |
| Depreciation | 1.11 | 0.5 | 0.54 | 0.5 | 0.47 | 0.52 | 1.16 | 0.9 |
| Profit before tax | 6.13 | 5.81 | 3.96 | 5.87 | 6.06 | 6.64 | 4.67 | 4.92 |
| Tax % | 12.23% | 12.91% | 22.22% | 14.48% | 9.08% | 9.79% | 4.50% | 5.08% |
| Net profit | 5.38 | 5.06 | 3.07 | 5.01 | 5.51 | 6 | 4.46 | 4.67 |
| EPS (₹) | 0.21 | 0.20 | 0.10 | 0.20 | 0.21 | 0.22 | 0.15 | 0.18 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Gennex Laboratories Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 60 | 61 | 66 | 87 | 138 | 173 | 183 |
| Operating profit | 7 | 5 | 5 | 17 | 17 | 22 | 26 |
| OPM % | 11% | 9% | 7% | 20% | 12% | 13% | 14% |
| Net profit | 4 | 4 | 5 | 13 | 18 | 21 | 21 |
| EPS (₹) | 0.21 | 0.21 | 0.28 | 0.58 | 0.80 | 0.76 | 0.76 |
TTM is the trailing twelve months to the most recent quarter.
Gennex Laboratories Ltd growth and returns
- 10 Years
- %
- 5 Years
- 24%
- 3 Years
- 38%
- TTM
- 24%
- 10 Years
- %
- 5 Years
- 34%
- 3 Years
- 57%
- TTM
- 14%
- 10 Years
- 6%
- 5 Years
- 10%
- 3 Years
- 13%
- 1 Year
- -1%
- 10 Years
- 9%
- 5 Years
- 10%
- 3 Years
- 10%
- Last Year
- 9%
Gennex Laboratories Ltd shareholding pattern
Promoters held 23.63% at Jun 2026, up from 19.82% at Jun 2025.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 18.41% | 18.41% | 18.41% | 19.82% | 23.62% | 23.62% | 23.63% | 23.63% |
| Public | 81.59% | 81.58% | 81.58% | 80.17% | 76.38% | 76.39% | 76.36% | 76.38% |
| No. of shareholders | 90,236 | 92,506 | 92,326 | 91,183 | 90,320 | 86,306 | 84,133 | 82,886 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Gennex Laboratories Ltd corporate filings
- Pursuant to Regulation 47 of SEBI (LODR) Regulations, 2015, please find enclosed herewith Newspaper publication on Unaudited (Standalone and Consolidated) Financial Results for the Quarter ....Company Updatelow impact
Cruxal's analysis: Gennex Laboratories Limited has released its unaudited financial results for the quarter…
Read the full analysis - In just concluded Meeting of Board of Directors, the Board Approved and considered the following items: 1. Unaudited (Standalone and Consolidated) Financial Statements for the Quarter ....Board Meetingmedium impact
Cruxal's analysis: Gennex Laboratories Limited has released its unaudited financial results for the quarter…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Gennex Laboratories Ltd
Cruxal reads every Gennex Laboratories Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.